Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Atricure ( (ATRC) ) has provided an update.
On January 9, 2026, AtriCure amended and extended its asset-based revolving credit facility with JPMorgan Chase and other lenders, securing a three-year extension of its credit agreement, lowering the interest rate, and removing a minimum utilization covenant on its up to $125 million facility, which can be increased to as much as $165 million; the facility, secured by a first-priority interest in substantially all borrower assets and guaranteed by AtriCure and its material domestic subsidiaries, is intended to fund working capital and general corporate purposes, strengthening the company’s liquidity and financial flexibility. On January 12, 2026, the company reported preliminary, unaudited results indicating fourth-quarter 2025 revenue of about $140.5 million, up roughly 13% year over year, and full-year 2025 revenue of approximately $534.5 million, up about 15%, driven by robust growth in pain management, open ablation and AtriClip devices; management expects 2025 adjusted EBITDA of $57 million to $59 million, an adjusted loss per share of $0.18 to $0.21, and year-end cash and investments of about $167 million, signaling improving profitability, operational leverage and a solid balance sheet ahead of the release of audited results and a detailed discussion on the upcoming earnings call in February.
The most recent analyst rating on (ATRC) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Atricure stock, see the ATRC Stock Forecast page.
Spark’s Take on ATRC Stock
According to Spark, TipRanks’ AI Analyst, ATRC is a Outperform.
Atricure’s overall stock score is driven by strong financial performance and positive technical indicators. The earnings call highlighted significant growth and raised guidance, contributing to a high score. However, valuation concerns due to negative profitability metrics slightly offset these strengths.
To see Spark’s full report on ATRC stock, click here.
More about Atricure
AtriCure, Inc., based in Mason, Ohio and listed on Nasdaq under the ticker ATRC, is a medical device company specializing in surgical treatments for atrial fibrillation (Afib), left atrial appendage management and post-operative pain management. Its portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, the globally leading AtriClip LAA exclusion system, Hybrid AF minimally invasive therapy for long-standing persistent Afib, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation to manage pain in cardiac, thoracic and amputation procedures. The company targets surgeons worldwide treating Afib and related complications, positioning itself as a key innovator in Afib and cardiac surgery technologies.
Average Trading Volume: 519,088
Technical Sentiment Signal: Buy
Current Market Cap: $2.11B
See more data about ATRC stock on TipRanks’ Stock Analysis page.